NeoGenomics initiated with a Buy at Jefferies

Jefferies analyst Tycho Peterson initiated coverage of NeoGenomics (NEO) with a Buy rating and $22 price target Larger full-service reference labs, such as NeoGenomics, stand to benefit from the same tailwinds as “esoteric labs,” but with less idiosyncratic National Provider Identifier commercialization and reimbursement risk, the analyst tells investors.